Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...

When treating obesity, semaglutide may be associated with a reduced fracture risk compared with sleeve gastrectomy.

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

A global trial reveals tirzepatide helps people lose more weight faster than semaglutide. This breakthrough could change ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can naturally mimic the effects of semaglutides.

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...